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ABSTRACT 
 
 As a central integrator of basal ganglia function, the external segment of the globus 
pallidus (GP) plays a critical role in the control of voluntary movement. The GP is composed 
of a network of inhibitory GABA containing projection neurons which receive GABAergic input 
from striatum (Str) axons and local collaterals of GP neurons. Here, using electrophysiological 
techniques and immunofluorescent labeling we have investigated the differential cellular 
distribution of α1, α2, α3 GABAA receptor subunits in relation to striato-pallidal (Str-GP) and 
pallido-pallidal (GP-GP) synapses. 
 Electrophysiological investigations showed that zolpidem (100 nM - selective for the α1 
subunit) increased the amplitude and the decay time of both Str-GP and GP-GP IPSCs, 
indicating the presence of the α1 subunits at both synapses. However, the application of 
drugs selective for the α2, α3 and α5 subunits (zolpidem at 400 nM, L-838,417 and TP003), 
revealed differential effects on amplitude and decay time of IPSCs suggesting the non-
uniform distribution of non-α1 subunits.  
 Immunofluorescence revealed widespread distribution of the α1 subunit at both soma 
and dendrites, while double- and triple-immunofluorescent labeling for parvalbumin, 
enkephalin, gephyrin and the γ2 subunit, indicated strong immunoreactivity for GABAA α3 
subunits in perisomatic synapses, a region mainly targeted by local axon collaterals. In 
contrast, immunoreactivity for synaptic GABAA α2 subunits was observed in dendritic 
compartments where striatal synapses are preferentially located. Due to the kinetic properties 
which each GABAA α subunits confer, this distribution is likely to differentially contribute to 
both physiological and pathological patterns of activity.   
      
 
                                                                                                                             
 
INTRODUCTION 
 The basal ganglia (BG) consist of a group of nuclei involved in a variety of functions, 
including motor control, and are the principal site of pathology in a variety of diseases 
including Parkinson’s disease. Driven by intrinsic mechanisms and excitatory glutamatergic 
inputs from the subthalamic nucleus (STN), neurons of the globus pallidus (GP, external 
segment of the globus pallidus in primates) process and transmit information from the 
striatum to the STN (Smith et al., 1990; Parent & Hazrati, 1995), the internal segment of the 
globus pallidus (Kincaid et al., 1991), the substantia nigra pars reticulate (Smith & Bolam, 
1989)  and the striatum (Bevan et al., 1998). Neurons of the GP are thus in a position to 
powerfully influence activity of the whole BG (Bolam et al., 2000). 
 The GP is composed of a network of inhibitory GABAergic projection neurons. Ninety 
percent of their afferent synapses are GABAergic, arising from the striatum and the axon 
collaterals of neighbouring GP neurons. The GP boutons preferentially innervate the soma 
and proximal dendrites of GP neurons (Kita & Kitai, 1994; Sato et al., 2000) in the form of 
peri-neuronal nets (Shink et al., 1996; Sadek et al., 2007). Electrophysiological studies (Sims 
et al., 2008) have revealed significant differences in the characteristics of striato-pallidal (Str-
GP) and pallido-pallidal (GP-GP) synapses which may be due to differential expression of 
GABAA subunits.  
 GABAA receptors are hetero-pentameric channels composed of a family of receptor 
subunits. Functional GABAA receptors require the co-assembly of 2α, 2β and one other 
subunit (Barnard, 1995; Tretter et al., 1997; Farrar et al., 1999), the  most common form 
being composed of 2α, 2β, 1γ (Ernst et al., 2003; Benke et al., 2004). Different subunits 
confer different pharmacological and electrophysiological properties (Sieghart, 1995). Thus, 
receptors containing the 1 subunit have fast deactivation and desensitization kinetics 
(Freund & Buzsaki, 1996; Klausberger et al., 2002), whereas those containing the α2 subunit 
show rapid activation but slow deactivation rates (Lavoie et al., 1997), and an apparent ten-
fold higher affinity for GABA (Levitan et al., 1988). The  subunit appears to be an integral 
part of the recognition site for GABA (Amin & Weiss, 1993) and has a role in receptor 
desensitization (Newell & Dunn, 2002) while the γ subunit, together with the α subunit, is 
associated with the benzodiazepine-binding site (Sieghart, 1995; Sigel, 2002; Ernst et al., 
2003) and is implicated in clustering at synaptic sites through interaction with the microtubule 
protein gephyrin (Ramming et al., 2000; Fritschy et al., 2008).   
 Previous reports indicate dense immunoreactivity for GABAA α1, 2, γ1 subunits and 
weaker immunoreactivity for GABAA α2, α3, 3 and γ2 subunits (Fritschy et al., 1992; Fritschy 
& Mohler, 1995; Pirker et al., 2000; Schwarzer et al., 2001) in the GP. In this study, our aim 
was to determine whether different GABAA receptor subunits are selectively associated with 
Str-GP and GP-GP synapses and thus underlie differences in the properties of the synapses. 
This was done by a combination of electrophysiological, pharmacological an 
immunofluorescence analyses.   
                       
             
MATERIALS AND METHODS 
 All the animals in this study were used in accordance with the Animals (Scientific 
Procedures) Act, 1986 (UK) and in accordance with the European Community Council 
Directive of 24th November 1986 (86/609/EEC).   
 
Electrophysiology 
 18-22 day old male Wistar rats used in this study were in bred from a colony originally 
obtained from Charles River (Kent, U.K.). Rats were first anaesthetized with isoflurane in 2% 
O2 until cardio-respiratory arrest and then decapitated. Brain slices (300 µm) were then cut on 
a DTK-1000 Microslicer (Dosaka, Japan) in a sucrose-based solution comprising (mM): 
sucrose, 206; KCl, 2.5; CaCl2.2H2O, 1; NaHCO3, 26; NaH2PO4, 1.25; MgCl2.6H2O, 2; 
glucose, 10; indomethacin, 0.045. The slices were then incubated at room temperature for 1 h 
in artificial cerebrospinal fluid (aCSF) comprising (in mM): NaCl, 126; KCl, 2.5; CaCl2.2H2O, 2; 
NaHCO3, 26; NaH2PO4, 1.2; MgCl2.6H2O, 1.3; glucose, 10. Cutting solution and aCSF were 
equilibrated with 95%:5% O2:CO2, pH 7.4. Slices were then transferred to a recording 
chamber perfused with aCSF at a rate of 2 ml/min, at 32oC. Neurons were visualized by 
differential interference contrast infrared microscopy using with an Olympus BX51W1 
microscope together with a CCD KP-M1 camera (Hitachi, Japan). 
 Whole-cell patch-clamp recordings were made using borosilicate glass pipettes (1.5-2.5 
MΩ resistance) and filled with a chloride-based internal solution, comprising (mM); KCl, 125; 
NaCl; 10, CaCl2, 1; MgCl2, 2; HEPES, 10; GTP, 0.3; Mg-ATP, 2; BAPTA, 10 (adjusted to pH 
7.3 with KOH). 
 Membrane currents were recorded in neurons voltage-clamped at -80 mV using an 
Axopatch 700A patch-clamp amplifier (Molecular Devices, U.S.A.).  Series resistance (3-20 
MΩ) was monitored throughout experiments and compensated > 60%. Results from neurons 
where series resistance changed over 20% throughout the analysis, or was greater than 20 
MΩ, were discarded. 
 Focal stimulation was applied with glass electrodes filled with aCSF, and carried out 
using a DS-3 isolated stimulator (Digitimer, U.K.) with pulses of 0.1 ms width and 0.02-1 mA 
at 0.2 Hz. To block NMDA and AMPA receptors that may have been activated by 
glutamatergic inputs from the STN or possibly the pedunculopontine nucleus, 50 µM 2-AP5 
and 10 µM CNQX was routinely added to the aCSF. Selective stimulation of Str-GP synapses 
and GP-GP synapses was achieved as described previously (Sims et al., 2008). In brief, for 
the stimulation of Str-GP connections, sagittal sections were used and electrodes were 
placed in dense axonal bundles within the striatum itself. For the stimulation of GP-GP 
connections, coronal sections were used, thus reducing the impact of Str-GP inputs. In these 
experiments stimulating electrodes were placed in the GP itself, away from striato-pallidal 
axonal bundles but within 200 µm of the recorded GP neuron.   
 The use of sagittal and coronal sections to separate Str-GP inputs from GP-GP inputs is 
based upon the knowledge that Str-GP projections project along the rostro-caudal axis 
(Wilson & Phelan, 1982) and that the dendritic arbour of many GP neurons lies perpendicular 
to this striatal input (Kita & Kitai, 1994). These planes of section have been used previously to 
separate Str-GP inputs from GP-GP inputs and show differential sensitivity to dopamine D2 
agonists (Cooper & Stanford, 2000) and Str-GP sensitivity to cannabinoid CB1 agonists 
(Engler et al., 2006). 
 Striatal inputs are therefore effectively negated in slices cut in the coronal plane, allowing 
stimulation of GP-GP inputs without extensive contamination. However, cross-stimulation is 
still a possibility as up to 30% of GP neurons project back to the striatum (Bevan et al., 1998). 
Thus, there was the potential that striatal stimulation antidromically activate GP axons which 
would contaminate presumed Str-GP responses. Antidromic responses were occasionally 
observed but were easily identified as the amplitude was directly proportional stimulation 
intensity and peaked within 0.1ms of the stimulation artefact. All data showing evidence of 
antidromic activity were discarded. We acknowledge that antidromic stimulation of other GP 
cells may take place, which may then release GABA onto our recorded cell.  However, the 
precise location and stimulation strength was manipulated to evoke IPSCs without failures 
and without multiple peaks which may arise through stimulation multiple fibres and/or the 
activation of polysynaptic networks.  
 Data were recorded at 10 kHz, and filtered by an 8-pole low-pass Bessel filter at 4 kHz 
using a Multiclamp 700A amplifier, and digitized by a Digidata 1322A. Analysis was 
performed online with Clampex 9.2 and offline using Clampfit 9.2 (all Molecular Devices, 
USA). The amplitude of each IPSC was measures from a point immediately before the 
stimulation artefact while decay times were calculated by fitting single exponential curves in 
Clampfit 9.2. In the data traces presented, stimulation artefacts were removed offline. All data 
is expressed as mean ± standard error mean, unless otherwise stated. The Mann-Whitney U-
test was used to assess differences from baseline recordings 15 minutes after drug 
application and P < 0.05 was considered significant. 
 
Drugs 
 2-AP5 and CNQX were supplied by Ascent Scientific (U.K.), diazepam (non-selective 
benzodiazepine) from Sigma UK and zolpidem (selective for the GABAA1 subunit) and L-
838,417 (selective efficacy for GABAA α2, α3 and α5 subunits) from Tocris (U.K.). TP003 
(GABAA α3 subunit selective agonist) was supplied by and used with the permission of Merck 
Research Laboratories (New Jersey, USA). All drugs were initially made in 1000x stock 
solutions and diluted to the final concentration in aCSF immediately prior to application. 
 
Immunofluorescent labeling 
 Immunofluorescent localization of GABAA receptor subunits can often yield false negative 
or unspecific labeling as some of these proteins are sensitive to the aldehyde concentrations 
used in fixation process. Therefore, we optimised our fixation protocol to reach the most ideal 
labeling, using 1% paraformaldehyde and low pH fixation for the 3 experiments, and 2% 
paraformaldehyde in combination with pepsin digestion for all the other immunoreactions.  
          Six adult Sprague-Dawley rats (250-450 g; Charles River, Margate, U.K.) were used. 
Each animal was anesthetized with phenobarbital, and perfused with approximately 50 ml of 
phosphate buffered saline (PBS; 0.01 M phosphate buffer, pH 7.4, 0.876% NaCl, 0.02% KCl) 
via the ascending aorta, followed by about 200 ml of fixative (0.1 M phosphate buffer, pH 7.4, 
1 or 2% paraformaldehyde, 15% saturated picric acid) over a period of 25 min. For the GABAA 
α3 subunit experiments the fixative consisted of 1% paraformaldehyde in Na-acetate buffer at 
pH 6. Free fixative was removed by post-perfusion with PBS. The brains were removed and 
60 µm sagittal sections cut using a vibrating blade microtome (VT1000S; Leica). 
 Sections for most of the immunoreactions (except the reactions with the α3 antibody, 
where no pepsin treatment was used) were washed in 0.1 M phosphate buffer (PB), and then 
treated with 0.02% pepsin (P-7125, Sigma-Aldrich Chemie, Steinheim, Germany) to unmask 
the antigens and epitopes thus enhancing staining intensity. Sections were pre-incubated for 
2 h at room temperature in blocking solution, consisting of 20% normal donkey serum, 0.2% 
Triton X-100 in Tris buffered saline (TBS; 50 mM, pH 7.5, 0.9% NaCl). This was followed by 
overnight incubation at 4 °C with one or mixtures of primary antibodies against: GABAA 
subunits (α1, α2, α3, γ2), gephyrin, parvalbumin, enkephalin, vesicular GABA transporter 
(VGAT) and anti-human neuronal protein (anti-HuC/D). 
 Details of origin, specificity and dilutions of antibodies are described in Table 1.  Sections 
were then washed and incubated in mixture of fluorescent tagged secondary antibodies. 
Finally, sections were washed, mounted and cover-slipped using fluorescence mounting 
medium (Vectashield, Vector Laboratories, Inc., Burlingame, CA, U.S.A.). 
 
Controls 
 The specificity of GABAA α1, α2, α3 and γ2 antibodies have all been previously tested in 
knock-out animals (see Table 1 for references). To test for cross-reactivity between various 
antibodies sections were processed with a full complement of secondary antibodies and one 
primary antibody at a time. None of the combinations with species-unrelated secondary 
antibodies resulted in labeling. In addition, no selective labeling was found in sections 
incubated with combinations of secondary antibodies without a primary antibody (see 
supplementary Table). 
 
Imaging and data acquisition 
 Images were captured with a LSM 710 (Zeiss, Göttingen Germany) confocal microscope 
with; Plan-Apochromat 63x/1.40 oil and 40x/1.3 or 20x objectives. For low magnification LSM 
images 10x objective was used. The ZEN 2008 software’s default settings for the fluorophors 
were used for beam splitters and ranges of emissions sampled. Two channel z-stacks were 
acquired using the SRS automatic acquisition function, following a manual pre-
focussing step at all capture sites, and projection images were analyzed. However, for 
a better quality, single images are presented in the figures. For stereological analysis, 
three sections from two animals were analyzed using a fluorescence capable Stereo-
Investigator system (MBF Biosciences, MicroBrightField Europe, Magdeburg, Germany). The 
boundary of the GP was drawn at low (10x objective) magnification. A sampling grid was 
randomly positioned over the GP contour. The sizes of grids were chosen according to the 
abundance of analyzed neurons (240 x 180 m for α1-HuC/D and 375 x 270 m for α1-
gephyrin experiments).  A counting frame of 125 x 90 m was located at the top left of each 
grid cell.  
 
RESULTS 
 IPSCs were evoked either by stimulation within the GP in coronal slices selectively 
activating GP-GP synapses or by stimulation in the striatum in sagittal slices selectively 
activating Str-GP synapses. Previous studies (Sims et al., 2008) have revealed differences in 
the kinetics of these evoked IPSCs and this was confirmed in the current experiments.  Thus, 
rise times, decay times and half widths of Str-GP responses were significantly slower than 
GP-GP synapses, data which is consistent with local collaterals innervating the soma and 
proximal dendrites of GP neurons and striatal inputs preferentially innervating more distal 
regions.  
 In the first series of experiments the non-subunit selective benzodiazepine, diazepam 
was used. Diazepam (500 nM) increased the Str-GP evoked IPSC amplitude (130.7 ± 10.3%, 
n= 6, P = 0.0006, Mann-Whitney U-test) and GP-GP evoked IPSC amplitude (141.3 ± 15.4%, 
n = 6, P = 0.0012, Mann-Whitney U-test) after 15 min application (Fig. 1A/1-A/2). As expected 
from a benzodiazepine-mediated action, the decay time of the Str-GP and GP-GP evoked 
responses also significantly increased (129.0 ± 5.5%, n=6, P = 0.0006 and 132.4 ± 8.9%, 
n=6, P = 0.0012, Mann-Whitney U-test) respectively (Fig. 1A/3-A/4). 
 In order to probe for the presence of GABAA α1-subunit density at Str-GP and GP-GP 
synapses, zolpidem was used at 100 nM, a concentration at which it shows selectivity for the 
α1 subunit. At this concentration, zolpidem increased the Str-GP evoked IPSC amplitude 
(141.1 ± 13.7%, n = 6, P = 0.0012, Mann-Whitney U-test) and the GP-GP evoked IPSC 
amplitude (147.0 ± 12.3%, n=6, P = 0.0012, Mann-Whitney U-test) after 15 min application 
(Fig. 1B/1-B/2). The decay time of the Str-GP and GP-GP evoked responses also increased 
(137.7 ± 12.5%, n=6, P = 0.0221 and 140.7 ± 8.0%, n=6, P =0.0012, Mann-Whitney U-test) of 
baseline respectively (Fig. 1B/3-B/4). These data suggest that GABAA receptors containing 
the α1 subunit are located at both Str-GP and GP-GP synapses.   
 To complement the pharmacological data, we analyzed the cellular distribution of the 
GABAA α1 subunit. Strong immunoreactivity for the GABAA1 subunit was detected 
throughout the GP (Fig. 2A). In order to determine the proportion of GP neurons that express 
the GABAA1-subunit, double-labeling for the 1-subunit with the neuronal marker HuC/D 
was carried out and the numbers of single- and double-labeled neurons counted in a sample 
of 3 sections from 2 animals. From these counts, we estimate that 80.6% (710 of a total 
number 881 neurons counted) of the total population of GP neurons express GABAA1 
subunit whereas the expression of the subunit was not detected in 19.4%.  
 GP neurons can be characterized based on the expression of the calcium binding 
protein, parvalbumin. Therefore, to determine whether the receptor subunits are expressed in 
parvalbumin-negative or parvalbumin-positive GP neurons, we performed triple-labeling 
experiments for GABAA α1, gephyrin and parvalbumin (Fig. 2B-E). We found that GABAA α1 
subunit was co-localized with gephyrin and equally distributed on the soma (Fig. 2E, double 
arrowheads) and on dendrites of parvalbumin-positive and negative GP neurons (Fig. 2E, 
arrowheads).  
 We acknowledge that the co-localization of gephyrin with the 1 subunit does not 
necessarily provide direct evidence for the synaptic location of the receptor subunit, since 
previous studies have reported both gephyrin-dependent and gephyrin-independent 
clustering of synaptic GABAA 1 subunit containing receptors (Kneussel et al., 2001, Levi et 
al., 2004). Indeed, this correlates with the observation that the population of GABAA1-
positive neurons expressed variable levels of gephyrin immunoreactivity within the soma. One 
group displayed only slightly stronger immunolabeling over background (Fig. 2C asterisk), 
whereas the immunolabeling of the other group was considerably higher than background 
(Fig. 2E arrows). This finding raises the question, whether neurons expressing low levels of 
gephyrin receive less inhibitory input, or express some other postsynaptic clustering protein. 
To address this question triple labeling immunofluorescent experiments were preformed with 
GABAA1, gephyrin and VGAT. Qualitative analysis revealed that in both the weak and 
strong gephyrin-immunoreactive neurons, immunoreactivity for GABAA 1 (Supp. Figure 1A) 
subunit and VGAT (Supp. Figure 1C) was equally strong (Supp. Figure 1D).  Thus, both 
weakly and strongly gephyrin-immunoreactive GP neurons may equally be targeted by 
putative GABAergic terminals, suggesting that weakly gephyrin-positive GP neurons express 
some other protein besides gephyrin as a postsynaptic clustering protein.  
 Quantitative analysis of the GABAA1-gephyrin double-labeling experiments revealed 
that 76 % of 1-positive neurons in the GP are strongly positive for gephyrin (104 out of a 
total number of 136 neurons counted in 3 sections from 2 animals), as opposed to the 
remaining 24%, which are weakly positive for the synaptic marker (32 out of a total number 
136 neurons counted in 3 sections from 2 animals) (Fig. 2F). Interestingly, those neurons that 
showed strong immunoreactivity for gephyrin were also positive for parvalbumin (Fig. 2E, 
arrows), whereas neurons showing low levels of gephyrin immunoreactivity appeared to be 
parvalbumin-negative (Fig. 2E, asterisk).   
 In addition to double labeling for gephyrin and GABAA α1, we performed further double 
labeling experiments with antibodies against GABAA γ2 subunit, which has also been shown 
to be required for postsynaptic clustering (Essrich et al., 1998).  These experiments revealed 
the co-location of the GABAA α1 subunits with the GABAA γ2 subunit at both somatic and 
dendritic locations (Fig. 2K-M), similar to what we found with gephyrin.  
 Additionally, we determined whether we could detect any preferential localization of the 
GABAA α1 subunit associated with striatal afferent terminals.  In order to identify striatal 
terminals targeting GP neurons, we preformed double labeling experiments with enkephalin 
antibodies. Taking into account that a small proportion of GP neurons have been shown to 
express preproenkephalin, a precursor for enkephalin (Voorn et al., 1999; Hoover and 
Marshall 2002), it is still reasonable to suggest that the majority of the very dense enkephalin- 
immunoreactive terminals that are observed in GP are derived from the striatum (Fig. 2H). In 
all examined GABAA α1 subunit-expressing neurons enkephalin immunoreactivity appeared 
to be distributed equally with somata and dendrites (Fig. 2G-J and 2J/1-4). This suggests that 
GABAA α1 subunit is equally associated with striatal and GP synapse, which is consistent 
with the electrophysiological data (see above).   
 At 100 nM, zolpidem is considered to be selective for GABAA receptors containing the α1 
subunit whilst 400 nM zolpidem is considered non-selective, having significant efficacy also at 
GABAA α2 and α3 subunit-containing receptors (Langer S.Z, 1992). In order to probe for the 
presence of GABAA receptors containing non-α1 subunits at Str-GP and GP-GP synapses, 
IPSC amplitude and decay time were monitored whilst raising the concentration of zolpidem 
from 100 nM to 400 nM (Fig 3). This change in concentration had no effect on the amplitude 
of Str-GP IPSCs (94.4 ± 5.8%, n=8, P = 0.7308, Mann-Whitney U-test, Fig. 3A/1), but 
increased GP-GP IPSC amplitude (112.6 ± 3.7%, n=8, P = 0.0012, Mann-Whitney U-test, Fig. 
3A/2) after 15 min application.  However, the decay time of the evoked Str-GP and GP-GP 
IPSCs both increased to 111.4 ± 3.0% (n=8, P = 0.0023, Fig. 3A/3) and 118.6 ± 5.4% (n=8, P 
= 0.0047, Mann-Whitney U-test, Fig. 3A/4) respectively. The greater effect on GP-GP IPSCs 
of raising zolpidem concentration to 400nM, suggests that there is a higher density of non-α1 
subunits at GP-GP synapses. To further test these data, experiments were carried out with L-
838,417, an anxiolytic non-benzodiazepine compound that has no efficacy at GABAA α1 
subunits but acts as a partial agonist at α2, α3 and α5 subunits (McKernan et al., 2000). L-
838,417 (500nM) had little effect on the amplitude of Str-GP IPSCs (104.5 ± 11.3%, n=6, P = 
0.4452, Mann-Whitney U-test, Fig. 3B/1) or decay time (103.6 ± 5.7%, n=6, P = 0.6282, 
Mann-Whitney U-test, Fig. 3B/3), but significantly increased the amplitude (129.3 ± 12.1%, 
n=7, P = 0.0262, Mann-Whitney U-test, Fig. 3B/2) and decay time (125.2 ± 5.1%, n=7, P = 
0.0005, Mann-Whitney U-test Fig. 3B/4) of GP-GP IPSCs. 
 To assess which non-α1 subunit is responsible for the enhancement of the amplitude and 
decay time at GP-GP synapses (Fig. 3), immunofluorescent labeling for the GABAA α2 
subunit was carried out.  Weak-to-moderate immunoreactivity for GABAA α2 was found 
throughout the GP (Fig. 4A).  The majority of GABAA α2-positive neurons examined were 
once again positive for parvalbumin (Fig. 4D, E). Although immunoreactivity for GABAA α2 
subunit was found in both somatic and dendritic compartments of individual GP neurons (Fig. 
4B, E/1), a clearly stronger immunoreactivity for the GABAA α2 subunit was observed in the 
dendrites (Fig. 4E/1, F).  
Double immunofluorescent labeling for GABAA α2 subunit and gephyrin revealed well-
defined co-localization in dendritic compartments whereas co-localization was less 
pronounced at the soma. This suggests relatively more synaptic GABAA α2 subunits in the 
dendrites of GP neurons (Fig. 4E-H). 
 The observation that the GABAA α2 subunit appears preferentially located in dendritic 
compartments raises the question which subunit is responsible for the increased GP-GP 
responses observed in the presence of 400 nM zolpidem and L-838,417? As zolpidem has 
been reported to be ineffective at GABAA α5 subunit-containing receptors (Pritchett & 
Seeburg, 1990; Langer S.Z, 1992) the most likely candidate is the GABAA α3 subunit. In order 
to test this possibility, immunofluorescent labeling for GABAA α3 subunit was carried out in 
combination with immunolabeling for α1 and γ2 subunits, enkephalin, parvalbumin and HuC/D 
(Fig. 5A-D). Weak-to-moderate immunoreactivity for GABAA α3 subunits was observed 
throughout the GP (Fig. 5A). The immunoreactivity for this subunit appeared to be both 
intracellular and membrane associated. In contrast to the α2 subunit immunoreactivity, the α3 
subunit appeared to be more pronounced at the soma than in dendritic compartments (Fig. 
5B, E, H, and L). Once again, gephyrin showed strong immunoreactivity throughout GP (Fig. 
5F), whereas double-labeling with GABAA α3 was mainly observed at the soma (Fig. 5G). 
Dense immunoreactivity for enkephalin was observed throughout the somato-dendritic axis of 
GP neurons (Fig 5I); immunoreactivity which was clearly associated with GABAA α3 subunit-
positive and parvalbumin-positive neurons (Fig. 5K). Although immunoreactivity for the 
synaptic marker GABAA γ2 subunit was found at both somatic and dendritic locations, co-
localization with the GABAA α3 subunit was mainly observed at the soma (Fig 5L-N). As GP-
GP synapses form peri-neuronal nets on the soma and proximal dendrites of GP cells (Shink 
et al., 1996; Sadek et al., 2007) it is expected that the GABAA receptors, containing the α3 
subunit are preferentially targeted by local axon collaterals arising from other GP neurons.  
 To test for the presence of GABAA α3 subunits at GP-GP synapses we used the non-
benzodiazepine TP003 (100 nM) which has significant selectivity at receptors containing α3 
subunits (Dias et al., 2005). After 15 min application of 100 nM TP003, IPSCs evoked in 
sagittal slices by stimulation of the striatum showed no significant change in amplitude (97.5 ± 
4.8% n=7, P = 0.0973, Mann-Whitney U-test, Fig. 6A/1) or decay time (102.9 ± 5.8%, n=7, P 
= 0.0973, Mann-Whitney U-test, Fig. 6A/2). In contrast, IPSCs evoked in coronal slices by 
stimulation of GP showed significantly enhanced amplitude (125.0 ± 10.1%, n=7, P =0.0023, 
Mann-Whitney U-test, Fig. 6B/1) without significant change in decay time (108.7 ± 5.9%, n=7, 
P = 0.0734, Mann-Whitney U-test Fig. 6B/2). These data provide further evidence for a role of 
the α3 subunit at GP-GP synapses.  
 
DISCUSSION 
 Neurons of the GP receive inhibitory GABAergic input from the striatum and also from 
neighbouring neurons. Although not as dense as the striatal input, GP-GP synapses mainly 
innervate the soma and proximal dendrites where they form synapses in a peri-somatic 
basket-like pattern (Kita & Kitai, 1994; Sadek et al., 2007). In this study we have used this 
feature to correlate the properties of somatic GP-GP synapses and widespread Str-GP 
synapses with specific GABAA α subunits. 
 Using zolpidem at a low concentration we have shown GABAA α1 subunit to be present 
in both GP-GP and Str-GP synapses. Furthermore, immunocytochemical data reveals a 
widespread distribution of the GABAA α1 subunit being present in both dendritic and somatic 
compartments. It is likely that the majority of GABAA α1 subunits are located within the 
synapse as they co-localize with the synaptic markers gephyrin and the GABAA γ2 subunit.  
In contrast, the GABAA α2 and α3 subunits show a differential subcellular distribution.  The α2 
subunit appeared to be preferentially located at distal dendritic compartments, where it is co-
localized with gephyrin, whereas immunoreactivity for GABAA α3 subunit was confined to 
perisomatic regions where it co-localized with gephyrin and the γ2 subunit. Unfortunately 
quantification of immunofluorescent puncta in GP was not possible due to the relatively poor 
labeling observed. This problem is most likely due to the anatomical properties of GP itself as 
simultaneous experiments using cortical and hippocampal tissue provided convincing, 
punctate labeling with both the GABAA 2 and 3 antibodies. Quantification of these subunits 
was also attempted at ultra-structural level using electron microscopic analysis; however, 
once again poor labeling limited our analysis. Therefore, we were restricted to a qualitative 
light microscopic analysis complemented by the pharmacological and electrophysiological 
data. 
 
Cellular distribution 
 In brain slice preparations, medium spiny projection neurons of the striatum display 
hyperpolarized resting membrane potentials commonly around -90mV and are therefore 
quiescent (Jiang & North, 1991). In contrast, the majority of GP neurons exhibit spontaneous 
activity (Nambu & Llinas, 1994; Cooper & Stanford, 2000). Based on the assumption that Str-
GP inputs are more numerous, we initially thought that analysis of spontaneous action 
potential-driven IPSCs (arising from GP) and miniature IPSCs (the majority of which are 
presumed to be Str-GP in origin), should separate GP-GP and Str-GP activity. However, no 
kinetic differences between spontaneous or miniature IPSCS were observed leaving little 
confidence in the use of this type of analysis in the separation of these inputs. However, 
significant differences in the kinetics of evoked IPSCs were observed in coronal and sagittal 
slices indicating a better separation of GP-GP and Str-GP IPSCs. Thus, a typical GP-GP 
IPSC exhibits fast rise time, rapid decay and short half width while IPSCs elicited by Str-GP 
synapses are kinetically slower and significantly different from GP-GP IPSCs (Sims et al. 
2008).   
 In order to differentiate between α-subunits pharmacologically, we initially used the 
hypnotic drug, zolpidem at 100 nM and 400 nM. When tested on recombinant receptors, 
zolpidem displays a high affinity at α1-containing GABAA receptors (α1β2γ2, α1β3γ2: Ki=20 
nM), medium affinity at α2- and α3-containing GABAA receptors (e.g. α2β1γ2, α3β1γ2: Ki=400 
nM) and was ineffective at α5 subunit-containing receptors (α5β3γ2, α5β2γ2: Ki 5000 nM, 
(Pritchett & Seeburg, 1990; Langer S.Z, 1992). Furthermore, with regard to potency, an 
approximate 5 to 8 fold higher zolpidem concentration was required to generate a comparable 
enhancement of GABA-induced chloride flux in α2β3γ2 or α3β3γ2 receptors (see 
Ramerstorfer et al., 2010 and references therein).  We therefore maintain the concentrations 
of 100 nM and 400 nM zolpidem are good choices in order to differentiate between α1 and 
α2/α3 subunit containing receptors. This is further evidenced by the work of Crestani and 
colleagues (2000) who showed unequivocally, using mutated α1 subunits, that zolpidem 
acted as a sedative exclusively through α1-subunit containing GABAA receptors. 
 The GABAA γ2 subunit also appears critical for the activity of zolpidem (Cope et al., 
2004). Previously it has been reported that GABAA γ2 subunits are only present in the 
dendrites of GP neurons (Schwarzer et al., 2001). Furthermore, enkephalin-positive medium 
spiny striatal neurons have been reported to exclusively innervate the dendritic shafts of GP 
neurons (Falls et al., 1983; Okoyama et al., 1987). This gave rise to the notion that striatal 
derived afferents preferentially innervate the dendrites of GP neurons and contain GABAA γ2 
subunits. However, the data presented here indicates that GABAA γ2 subunits, as well as 
enkephalin-positive striatal axons and terminals, are more uniformly distributed over the 
whole GP neuronal architecture being present at both somatic and dendritic compartments.  
 Using zolpidem at a concentration of 100 nM we have shown GABAA receptors 
containing the α1 subunit are located at both Str-GP and GP-GP synapses. Increasing 
zolpidem to a non-selective concentration (400 nM), caused an increase in amplitude of GP-
GP but not Str-GP IPSCs, suggesting a larger proportion of non-α1 subunits at GP-GP 
synapses; a finding supported by the observations using the GABAA α3 selective drug TP003. 
Thus, both GABAA α1 and α3 subunit-containing receptors were preferentially found in the 
soma and regions of proximal dendrites where they would be selectively targeted by axon 
collaterals of other GP neurons (see Fig. 7). This also raises the possibility of localization of 
α1 alone or in combination with α3 (see Fig. 5D) (Benke et al., 2004). 
 
Subcellular distribution of α-subunits.    
  Using double immunolabeling we have demonstrated the co-localization of GABAA α1 2 
and α3 subunits with the GABAA γ2 subunit and gephyrin, which we used as a potential 
marker for synaptic sites, thus indicating the synaptic localization of these α subunits. 
However, a significant proportion of the receptor subunits did not co-localize with gephyrin or 
the γ2 subunit, possibly indicating that some subunits may be located extrasynaptically. 
Another possible explanation is that some GABAA receptor subunits may not require gephyrin 
for postsynaptic clustering. However the precise nature of these GABAA receptors remains 
unclear. It is currently accepted that the γ subunit is required for postsynaptic clustering, while 
the δ subunit confers extrasynaptic location when coupled to the α4 or α6 subunit (Nusser et 
al., 1998). The activation of extrasynaptic receptors give rise to tonic, background inhibitory 
conductance which can alter the input resistance of the neuron and influence synaptic 
efficacy and integration (Farrant & Nusser, 2005). However, there have been no reports 
indicating the presence of the δ subunit or indeed the presence of tonic inhibitory 
conductance in the GP.  If a tonic conductance is present in GP, the results presented here 
would indicate that α1, γ2 zolpidem-sensitive receptors may be involved (Semyanov et al., 
2003).  
 
Functional Implications. 
 The activation of GABAA receptors provides inhibition on the millisecond time-scale and 
has therefore been implicated in regulating the temporal dynamics of neural networks (Cobb 
et al., 1995; Traub et al., 1996; Mann & Paulsen, 2007; Yamawaki et al., 2008), both in 
physiological and pathological states. With regard to the basal ganglia and the Parkinsonian, 
dopamine-depleted state, exaggerated oscillatory activity in the GP amongst other nuclei, is 
invariably found at a frequency in the  range (~20Hz), which is implicated in the loss of ability 
to perform discrete movements in both Parkinson’s disease patients (Brown & Marsden, 
1998; Levy et al., 2000; Kuhn et al., 2006) and animal models of Parkinson’s disease (Mallet 
et al., 2008). Indeed, GABAA receptor-mediated IPSPs in the STN and GP appear to not only 
provide tonic inhibition of downstream nuclei but also have a role in determining the timing of 
subsequent action potential firing by producing rebound spikes and  phase realignment of the 
intrinsic subthreshold membrane oscillations (Bevan et al., 2002; Stanford, 2003; Rav-Acha et 
al., 2005). 
 It is widely accepted that peri-somatic inhibition primarily controls timing of activity and 
ultimately the regulation of overall neuronal output (Cobb et al., 1995; Miles et al., 1996; 
Freund & Katona, 2007). Moreover peri-somatic inhibition usually involves larger synaptic 
terminals, more synaptic vesicles and mitochondria, and larger active zones inducing IPSPs 
with faster kinetics and greater amplitude than those induced by dendrite-targeting 
interneurons (Miles et al., 1996). This is certainly the case in the GP where peri-neuronal nets 
of GP-GP terminals activate receptors containing α1 and α3 subunits on soma and proximal 
dendrites which would be expected to determine direct on/off signalling of activity. This finding 
also correlates with the peri-somatic innervation by terminals of other PV-positive GP neurons 
which constitute around 70% of the whole GP neuronal population (Kita, 1994). It remains to 
be determined how neuronal heterogeneity within the GP increases the complexity of the 
proposed schema. In contrast, dendritic inhibition may control the shunting and therefore 
efficacy of excitatory synaptic inputs or synaptic plasticity perhaps through the modulation of 
dendritic calcium spikes (Miles et al., 1996). In the hippocampus, parvalbumin-negative 
synapses showed five times more immunoreactivity for the GABAA α2 subunit than synapses 
made by parvalbumin-positive basket cells (Nyiri et al., 2001; Klausberger et al., 2002). This 
rule appears to hold in the GP, where α2 subunit containing receptors are preferentially 
located at synapses targeting distal dendrites in regions where parvalbumin-positive input 
would be restricted.  
 In conclusion, our data suggest that the synapses formed by  inhibitory terminals arising 
from the striatum and local axon collaterals from GP neurons, and target distinct neuronal 
compartments are associated with different complement of GABAA receptor subunits. These 
data add to the growing literature that each input will mediate different physiological functions. 
 
 
ACKNOWLEDGMENTS 
This work was supported by The Medical Research Council UK, Grant G0300179. Many 
thanks to Prof. Jean-Marc Fritschy for the gift of antibodies, Ben Micklem for his help with the 
imaging and stereology, Liz Norman, Katie Withworth and Caroline Francis for technical 
assistance and to Prof. P. Somogyi for helpful discussions.  
 
 
 
ABBREVIATIONS 
 
  BG   - basal ganglia 
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PRIMARY 
ANTIBODIES 
against 
SPECIES 
and 
DILUTIONS 
SOURCE and 
CHARACTERIZATION 
SECONDARY 
ANTIBODIES  
DILUTION 
and SOURCE 
NUMBER 
OF 
SECTIONS 
/ NUMBER 
OF 
ANIMALS 
  
GABAA1 
 
Rabbit 
(1:10000) 
 
(Fritschy and Mohler, 
1995) 
 
donkey--rb 
Alexa 488 
(1:1000); CY5 
(1:250) 
 
10/5 
 
GABAA2 
 
Rabbit 
(1:1000) 
 
(Kasugai et al., 2010) 
 
donkey--rb 
Alexa 488 
(1:1000) 
Invitrogen, 
Molecular 
Probes 
 
5/3 
 
       GABAA3 
 
Guinea-pig 
(1:4000) 
 
(Fritschy and Mohler, 
1995) 
 
donkey--gp 
CY3 (1:400) 
Jackson 
Laboratories 
 
8/4 
 
GABAA 2 
 
Rabbit 
(1:200) 
 
(Kasugai et al., 2010) 
 
donkey--rb 
Alexa 488 
(1:1000)  
Invitrogen, 
Molecular 
Probes 
 
3/3 
 
GABAA 2 
 
Guinea-pig 
(1:250) 
 
(Fritschy and Mohler, 
1995) 
 
donkey--gp 
CY3 (1:400) 
Jackson 
Laboratories 
 
3/3 
 
gephyrin 
 
Mouse 
(1:1000) 
 
Synaptic Systems 
#mAB7a 
(Jacob et al., 2005) 
(Schneider Gasser et 
al., 2006) 
 
donkey--m 
CY3 (1:400) 
Jackson 
Laboratories 
 
10/5 
 
parvalbumin 
 
Guinea-pig 
(1:1000) 
 
Synaptic Systems 
#195 004 
 
donkey--gp 
CY5 (1:250) 
Jackson 
Laboratories 
 
5/3 
 
enkephalin 
 
Mouse 
(1:500) 
 
Chemicon 
#MAB 350 
(Lindemeyer et al., 
2006) 
 
donkey--m 
CY3 (1:400) 
Jackson 
Laboratories 
 
5/3 
 
HuC/D 
 
Mouse 
(1:100) 
 
Molecular Probes 
#A-21271 
(Fornaro and Geuna, 
2005) 
 
donkey--m 
CY5 (1:250) 
Jackson 
Laboratories 
 
3/3 
 
 
VGAT 
 
Guinea-pig 
(1:500) 
Synaptic Systems  
#131 005 
(Gronborg et al., 2010) 
 
CY5 (1:250) 
Jackson 
Laboratories 
 
4/2 
 
Table 1. Details of primary and secondary antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
primary antibodies 
(dilution) 
secondary antibodies 
(dilution) 
experiment # 1     
  GABAA 1 (rb) (1:10000)   donkey ‐rb‐488 (1:1000) 
   gephyrin (m) (1:1000)   donkey ‐m‐CY3 (1:400) 
   PV (gp) ( 1:1000)   donkey ‐gp‐CY5 (1:250) 
CONTROL       
   x   donkey ‐rb‐488 (1:1000) 
   x   donkey ‐m‐CY3 (1:400) 
   x   donkey ‐gp‐CY5 (1:250) 
   GABAA 1 (rb) 1:10000   donkey ‐m‐CY3 (1:400) 
   x   donkey ‐gp‐CY5 (1:250) 
   gephyrin (m) 1:1000   donkey ‐rb‐488 (1:1000) 
   x   donkey ‐gp‐CY5 (1:250) 
   PV (gp)  1:1000   donkey ‐rb‐488 (1:1000) 
   x   donkey ‐m‐CY3 (1:400) 
experiment # 2       
   GABAA  (rb) ( 1:10000)   donkey ‐rb‐488 (1:1000) 
   Enk (m)  (1:500)   donkey ‐m‐CY3 ( 1:400) 
   PV (gp) ( 1:1000)   donkey ‐gp‐CY5 (1:250) 
CONTROL       
   Enk (m)  (1:500)   donkey ‐rb‐488 (1:1000) 
   x   donkey ‐gp‐CY5 (1:250) 
experiment # 3       
   GABAA  (rb) ( 1:10000)   donkey ‐rb‐488 (1:1000) 
   GABAA (gp) (1:250)   donkey ‐gp‐CY3 (1:400) 
CONTROL       
   x   donkey ‐gp‐CY3 (1:400) 
   GABAA  (rb) ( 1:10000)   donkey ‐gp‐CY3 (1:400) 
   GABAA (gp) ( 1:250)   donkey ‐rb‐488 (1:1000) 
experiment # 4       
   GABAA 1 (rb) (1:10000)   donkey ‐rb‐488 (1:1000) 
   GABAA  (gp) (1:4000)   donkey ‐gp‐CY3 (1:400) 
   HuCD (m) (1:100)   donkey ‐m‐CY5 ( 1:250) 
CONTROL       
   x   donkey ‐gp‐CY3 (1:400) 
   x   donkey ‐m‐CY5 (1:250) 
   GABAA 1 (rb) (1:10000)   donkey ‐gp‐CY3 (1:400) 
   x   donkey ‐m‐CY5 (1:250) 
   GABAA  (gp) (1:4000)   donkey ‐rb‐488 (1:1000) 
   x   donkey ‐m‐CY5 (1:250) 
   HuCD (m) (1:100)   donkey ‐rb‐488 (1:1000) 
 
     
 
experiment # 5       
   GABAA  (gp)  1:4000  goat ‐gp‐488 ( 1:1000) 
   gephyrin (m) 1:1000   donkey ‐m‐CY3 (1:400) 
CONTROL       
   x  goat ‐gp‐488 ( 1:1000) 
   GABAA  (gp) 1:4000   donkey ‐m‐CY3 (1:400) 
   gephyrin (m) 1:1000   goat ‐gp‐488 ( 1:1000) 
experiment # 6       
   GABAA  (gp)  1:4000   donkey ‐gp‐488 ( 1:1000) 
   Enk (m) 1:500   donkey ‐m‐CY3 (1:400) 
   PV(rb) 1:1000   donkey ‐rb‐CY5 (1:250) 
CONTROL       
   x   donkey ‐rb‐CY5 (1:250) 
   GABAA  (gp) 1:4000   donkey ‐rb‐CY5 (1:250) 
      donkey ‐m‐CY3 (1:400) 
  Enk (m) 1:500   donkey ‐gp‐488 ( 1:1000) 
     donkey ‐rb‐CY5 (1:250) 
  PV(rb) 1:1000   donkey ‐gp‐488 ( 1:1000) 
     donkey ‐m‐CY3 (1:400) 
experiment # 7       
  GABAA  (rb) (1:10000)   donkey ‐rb‐488 ( 1:1000) 
  gephyrin (m) 1:1000   donkey ‐m‐CY3 (1:400) 
  PV(gp) 1:1000   donkey ‐gp‐488 ( 1:1000) 
CONTROL       
  GABAA  (rb) (1:10000)   donkey ‐m‐CY3 (1:400) 
       donkey ‐gp‐488 ( 1:1000) 
experiment # 8       
  GABAA  (rb) (1:10000)   donkey ‐rb‐488 ( 1:1000) 
  GABAA (gp) (1:250)   donkey ‐gp‐CY3 (1:400) 
CONTROL       
  GABAA  (rb) (1:10000)   donkey ‐gp‐CY3 (1:400) 
experiment # 9       
  GABAA  (gp)  1:4000   donkey ‐gp‐488 ( 1:1000) 
  GABAA (rb) (1:250)   donkey ‐rb‐CY3 (1:400) 
CONTROL       
  x   donkey ‐rb‐CY3 (1:400) 
  GABAA  (gp)  1:4000   donkey ‐rb‐CY3 (1:400) 
   GABAA (rb) (1:250)   donkey ‐gp‐488 ( 1:1000) 
 
 
Supplementary table 1 :  Control experiments  
abbreviations: (m: mouse; rb: rabbit; gp: guinea pig)  
FIGURE LEGENDS 
Figure 1. The α1 subunit is widely distributed in GP and is present at both Str-GP and GP-GP synapses.   
(A) Diazepam (500 nM) was added after 10 min baseline recording. At both Str-GP (n=6, black) and GP-GP 
(n=6, red) synapses the IPSC amplitude (A/1 and A/2) and decay times (A/3 and A/4) were significantly 
increased. Each point represents the average of six responses. Data traces (once again average of six) are 
shown for baseline (dark) and after 15 min diazepam (light) for both Str-GP (A/5) and GP-GP (A/6) synapses.  
(B) 100 nM zolpidem (selective for α1 GABAA subunits) was added 10 min after baseline recording. At both Str-
GP (n=6, black) and GP-GP (n=6, red) synapses the IPSC amplitude (B/1 and B/2) and decay times (B/3 and 
B/4) were significantly increased. Data traces (average of six) are shown for baseline (dark) and after 15 min 
zolpidem (light) for both Str-GP (B/5) and GP-GP (B/6) synapses.  
 
Figure 2. GABAA   α1 subunit immunoreactivity in globus pallidus neurons  
(A): Low magnification confocal image showing strong immunoreactivity for the GABAA α1 subunit in GP and 
weak immunoreactivity in striatum. (B-E): Triple immunofluorescent labeling for the α1 subunit (green, B), 
gephyrin (red, C) and parvalbumin (blue, D). (B): GABAA α1 subunit immunoreactivity is widely distributed in the 
somata (arrows) and dendrites (arrowhead) of GP neurons. (C): GP neurons exhibit either strong (arrows) or 
weak (asterisk) gephyrin immunoreactivity. (D): Confocal image illustrating parvalbumin-positive (arrows) and 
negative neurons (asterix) in GP.  (E): Merged image showing that some GABAA α1 subunit-positive but 
parvalbumin-negative GP neurons (asterisk) show strikingly weak immunoreactivity for gephyrin, whereas other 
neurons (arrows) and dendrites (arrowhead) are immunoreactive for all three markers.  Scale in E also applies 
to B, C and D (F): Bar charts of the proportions of GP neurons expressing GABAA α1 subunit immunoreactivity 
(green) and the proportion of these that show strong (red) and weak (pink) immunoreactivity for gephyrin. (G-J): 
Triple immunofluorescent labeling showing GABAA α1 subunit- and parvalbumin-positive neurons closely 
apposed by enkephalin-positive striatal axon terminals. (H): Confocal image illustrating very dense enkephalin 
immunoreactivity in GP associated with somata (arrow) and dendrites (arrowhead). (I):  The same somata and 
dendrite as in H are immunopositive for parvalbumin. (J): Merged image showing GABAA α1 subunit and 
parvalbumin-positive cell bodies and dendrites closely apposed by many enkephalin-positive striatal axon 
terminals. Scale in G also applies to H, I and J. (J/1-J/4): High magnification confocal images of the dendrite 
fragment indicated by an arrowhead in G-H showing the co-occurrence of GABAA α1 subunit immunoreactivity 
with pre-synaptic enkephalin-immunoreactivity (arrowheads on J/4). Scale in J/4 applies to all four images. (K-
M): Confocal images of GP neurons expressing immunoreactivity for the GABAA α1 subunit co-localized with the 
GABAA γ2 subunit on somata (double arrowheads) and dendrites (arrowheads). Scale in M also applies to K and 
L.    
 
Figure 3. A greater number of non-α subunits at GP-GP synapses.  
(A) 400nM zolpidem was applied after 10 min baseline recording in 100nM zolpidem. IPSC amplitude (A/1 and 
A/2) and decay times (A/3 and A/4) were significantly increased at GP-GP (n=8, red) but not Str-GP (n=8, black) 
synapses.  (B) L-838,417 (500nM) was added 10 min after baseline recording. Once again, IPSC amplitude (B/1 
and B/2) and decay times (B/3 and B/4) were significantly increased at GP-GP (n=7, red) but not Str-GP (n=6, 
black) synapses. 
Figure 4 GABAA α2 subunits are preferentially located in synapses targeting the dendrites of GP 
neurons.  
(A): Low power confocal image showing weak/moderate immunoreactivity for the GABAA α2 subunit in GP and 
strong labeling in striatum. (B-E): In GP, triple immunofluorescent images illustrating immunoreactivity for the 
GABAA α2 subunit (green) and gephyrin (red) in a parvalbumin-expressing (blue) GP neuron. (B): Confocal 
image showing strong, mainly intracellular immunoreactivity for the α2 subunit in the soma (arrow), and punctate 
labeling in dendrites (arrowheads) of GP neurons. (C): Fluorescent image illustrating gephyrin immunoreactivity 
in somatic (arrow) and dendritic (arrowheads) compartments. (E): Merged image illustrating immunoreactivity for 
the GABAA α2 subunit (green) and gephyrin (red) in parvalbumin-expressing (blue) GP neuron somata (arrow) 
and dendrites (arrowheads). Scale in E also applies to B, C and D. (E/1-4): High magnification images of the 
dendritic segment in the boxed area in E. Note the co-localization of the GABAA α2 subunit immunoreactivity 
(green) with gephyrin immunoreactivity (red) (arrowheads in E/4). Scale in E/4 applies to all four images. (F-H): 
High power confocal images illustrating the numerous GABAA α2 subunit puncta associated with the gephyrin 
labeling (F, green, arrowheads).  Merged image in H.  Scale in H also applies to F and G. 
 
Figure 5.  Preferential localization of the GABAA α3 subunit at synapses targeting the soma of GP 
neurons. 
(A): Low power confocal image showing weak immunoreactivity for the GABAA α3 subunit in the GP and strong 
labeling in the striatum. (B-D): Low power images illustrating the co-localization of the two GABAA subunits; α1 
(C, red) and α3 (B, green) in GP neurons (arrows), identified by the neuronal marker, HuC/D (D, blue). (B): Note 
that GABAA α3 subunit immunoreactivity (green) is mainly present in the soma of GP neurons (arrows), as 
opposed to the GABAA α1 subunit immunoreactivity (red, C) which is distributed uniformly in the somatic and 
dendritic compartments. Scale in D also applies to B and C. (E): High power image of a GP neuron displaying 
strong immunoreactivity for the GABAA α3 subunit (green) at the soma (double arrowheads) and weaker 
labeling towards more distal dendritic compartments. (F): Strong gephyrin immunoreactivity (red) at both somatic 
and dendritic compartments indicating extensive inhibitory input to GP neurons. (G): Co-localization (double 
arrowheads) of the GABAA α3 subunit immunoreactivity (green) and gephyrin immunoreactivity (red) on the 
surface and intracellularly. Scale in G also applies to E and F. (H-K): A GABAA α3 subunit immunoreactive 
(green, H) and parvalbumin-positive (blue, J) GP neuron (arrow) closely apposed by enkephalin-positive 
boutons (red, I) on both somatic and dendritic compartments. Scale in K also applies to H, I and J. (L): Strong 
GABAA α3 subunit immunoreactivity (green) concentrated in the soma of a GP neuron (double arrowhead). 
Note the considerably weaker labeling observed on a nearby dendrite (arrowhead). (M): GABAA γ2 subunit 
immunoreactivity (red) showing strong labeling at both somatic and dendritic compartments of the same 
structures as in L. (N): Merged image illustrating the co-localization of the GABAA α3 subunit immunoreactivity 
(green) and GABAA γ2 subunit immunoreactivity (red) in the soma (double arrowhead) and the lack of co-
localization on a nearby dendrite (arrowhead). Scale in N also applies to L and M. 
 
 
 
 
Figure 6. The GABAA α3 subunit is preferentially located at GP-GP synapses.  
100 nM TP003 was added after 10 min of baseline recording. At Str-GP synapses (n=7, black) TP003 had no 
effect on both IPSC amplitude (A/1) and decay time (A/3), while at GP-GP synapses (n=7, red), TP003 
significantly increased the IPSC amplitude (A/2).  
 
 
Figure 7. Summary indicating cellular distribution of Str-GP and GP-GP synapses 
A GP neuron receives its major GABAergic input from striatum (STR terminals-purple) and from neighbouring 
GP neurons (GP terminals-light green) and glutamatergic input from STN (STN terminals-red) and to a lesser 
extent, from thalamus. Our results show an even distribution of the GABAA α1 subunits throughout the soma and 
dendritic axis of GP neurons. However, there is a differential distribution of the GABAA α2 and α3 subunits with 
the α2 preferentially located on the dendrites and α3 preferentially located at the soma where they are targeted 
by local GP collaterals.  
 
 
Supplementary Figure 1. GABAA   α1 subunit immunoreactivity in globus pallidus neurons  
Triple immunofluorescent labeling for the α1 subunit (green, A), gephyrin (red, B) and VGAT (blue, C).  
(A): Confocal image showing two GP neurons, both immunopositive for the GABAA1 subunit (arrow, asterisk). 
(B): Same GP neurons, expressing different levels of gephyrin immunoreactivity. While one neuron in strongly 
positive (arrow), the other one shows weak immunoreactivity for gephyrin (asterisk). (C): Confocal image 
illustrating the immunoreactivity for VGAT in the same GP neurons. (D): Merged image showing the labelling for 
GABAA1 (green), VGAT (blue) and gephyrin (red). VGAT immunolabeling shows similar distribution to the 
GABAA 1 subunit, and unlike gephyrin, no striking difference was observed in the intensity of the 
immunolabeling in these neurons.  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
